During the 15th edition of the CTAD (Clinical Trials on Alzheimer’s Disease) taking place from November 29 to December 2 of 2022 in San Francisco, USA, REGEnLIFE, a French company specialized in the research and development of innovative technologies in photo-medicine for the prevention and treatment of neurodegenerative diseases, presented the concept of its next clinical study, Light4life.
Dementia : new cases every 3.2 seconds worldwide
This pivotal study, which will be conducted in France in 2023 on 108 patients with Alzheimer’s disease, is designed to evaluate the cognitive impact of PhotoBioModulation (PBM), an innovative non-invasive therapy that acts on inflammation in the brain-gut axis, which is believed to be responsible for the development of Alzheimer’s disease and other neurodegenerative diseases. In 2020, more than 55 million people worldwide suffered from dementia. This number will almost double every 20 years, reaching 78 million in 2030 and 139 million in 2050. Currently, there is no treatment to cure this disease.
Based on these encouraging study results published in November in the Journal of Alzheimer’s Disease, REGEnLIFE will organize a multicenter pivotal study that will begin in early 2023 at the Toulouse University Hospital’s Gerontopole, directed by Professor Bruno VELLAS. 108 patients with mild to moderate Alzheimer’s disease will be treated for six months and followed for one year. […] We are taking advantage of our presence at CTAD to present this study project to our peers. We are very hopeful that this new study will provide another form of non-drug, non-invasive management for a disease for which we still do not have an effective treatment.“Professor Jacques TOUCHON, Neurologist, Scientific Advisor of REGEnLIFE and Co-Founder of CTAD
REGEnLIFE : an innovative technology against Alzheimer’s disease
An innovative, non-invasive and promising technology for the treatment of Alzheimer’s disease, REGEnLIFE’s PBM medical device called RGn600 uses photonic emissions in the infrared and will target both the brain and the gut of patients through a helmet, and abdominal belt. A pilot clinical trial conducted from 2018 to 2020, on about 50 patients aged 55 to 85 with mild to moderate Alzheimer’s disease, demonstrated the safety, ease of use of the treatment and improvement in some of the patients’ cognitive functions in just 2 months of intervention.
For Dr. Patrice CRISTOFINI, CEO of REGEnLIFE, the company’s participation in CTAD – a gathering of leaders in Alzheimer’s disease research from industry and academia – the publication of the pilot study in a leading scientific journal on Alzheimer’s disease, and the ongoing formation of a prestigious scientific advisory board, “will enable REGEnLIFE to take its place in the global market for Alzheimer’s disease treatments thanks to its innovative therapeutic approaches. It also makes a French contribution to this global public health issue.”